CTKB Key Statistics, Chart & Performance
The current stock price of CTKB is 5.6 USD. In the past month the price increased by 39.65%. In the past year, price decreased by -14.24%.
CTKB Latest News, Press Relases and Analysis
CTKB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 26.48 | 224.02B | ||
| DHR | DANAHER CORP | 29.63 | 163.59B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 189.06 | 57.37B | ||
| A | AGILENT TECHNOLOGIES INC | 27.66 | 43.76B | ||
| IQV | IQVIA HOLDINGS INC | 19.93 | 39.41B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.53 | 30.62B | ||
| WAT | WATERS CORP | 32.06 | 24.23B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.2 | 19.93B | ||
| ILMN | ILLUMINA INC | 29.77 | 19.95B | ||
| MEDP | MEDPACE HOLDINGS INC | 42.42 | 17.09B | ||
| TEM | TEMPUS AI INC | N/A | 13.41B | ||
| RVTY | REVVITY INC | 21.85 | 12.15B |
Related stock screener links
About CTKB
Company Profile
Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 688 full-time employees. The company went IPO on 2021-07-23. The firm is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.
Company Info
CYTEK BIOSCIENCES INC
47215 Lakeview Boulevard
Fremont CALIFORNIA US
Employees: 688
Phone: 18779229835
CYTEK BIOSCIENCES INC / CTKB FAQ
What does CYTEK BIOSCIENCES INC do?
Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 688 full-time employees. The company went IPO on 2021-07-23. The firm is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.
What is the stock price of CYTEK BIOSCIENCES INC today?
The current stock price of CTKB is 5.6 USD. The price decreased by -3.78% in the last trading session.
Does CYTEK BIOSCIENCES INC pay dividends?
CTKB does not pay a dividend.
What is the ChartMill technical and fundamental rating of CTKB stock?
CTKB has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for CTKB stock?
CYTEK BIOSCIENCES INC (CTKB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.1).
Can you provide the number of employees for CYTEK BIOSCIENCES INC?
CYTEK BIOSCIENCES INC (CTKB) currently has 688 employees.
What is the outstanding short interest for CYTEK BIOSCIENCES INC?
The outstanding short interest for CYTEK BIOSCIENCES INC (CTKB) is 5.54% of its float.
CTKB Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CTKB. When comparing the yearly performance of all stocks, CTKB is one of the better performing stocks in the market, outperforming 75.59% of all stocks.
CTKB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CTKB. CTKB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CTKB Financial Highlights
Over the last trailing twelve months CTKB reported a non-GAAP Earnings per Share(EPS) of -0.1. The EPS decreased by -25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.59% | ||
| ROE | -3.39% | ||
| Debt/Equity | 0 |
CTKB Forecast & Estimates
11 analysts have analysed CTKB and the average price target is 5.36 USD. This implies a price decrease of -4.37% is expected in the next year compared to the current price of 5.6.
For the next year, analysts expect an EPS growth of -308% and a revenue growth -3.3% for CTKB